Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy
Source · ClinicalTrials.gov: elamipretide
TLDR
ClinicalTrials.gov lists a completed Phase 1/2 trial of MTP-131 in 36 participants with mitochondrial myopathy associated with genetically confirmed mitochondrial disease. The study evaluated safety, tolerability, pharmacokinetics, and preliminary efficacy; the excerpt provides no results.
- 01The multi-center study was randomized, double-blind, and placebo-controlled.
- 02The trial enrolled 36 participants with genetically confirmed mitochondrial disease.
- 03Completed status is reported, but safety and efficacy findings are not provided.
Why it matters Editorial
The listing documents clinical evaluation in mitochondrial myopathy, but the excerpt does not establish treatment benefit or safety.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide